NTS 107
Alternative Names: NTS-107Latest Information Update: 03 Sep 2021
At a glance
- Originator Emory University
- Developer NeuroTrauma Sciences
- Class Neuroprotectants; Small molecules; Vascular disorder therapies
- Mechanism of Action Progesterone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Stroke; Traumatic brain injuries
Most Recent Events
- 26 Aug 2021 NTS 107 is available for partnering as of 26 Aug 2021. https://neurotraumasciences.com/
- 26 Aug 2021 Preclinical trials in Stroke in USA (unspecified route) as at August 2021 (NeuroTrauma Sciences pipeline; August 2021)
- 26 Aug 2021 Preclinical trials in Traumatic brain injuries in USA (unspecified route) as at August 2021 (NeuroTrauma Sciences pipeline; August 2021)